Brain Cancer Clinical Trials in Austin

Showing 61-80 of 122 trials

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

Brain CancerBrain NeoplasmGlioma+8 more

DNAtrix, Inc.49 participantsStarted Oct 2016

Little Rock, Arkansas, United States • Los Angeles, California, United States • Chicago, Illinois, United States +12 more locations

TERMINATEDPhase 362 miles

UNITE Study: Understanding New Interventions With GBM ThErapy

NCT03419403

The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).

Glioblastoma Multiforme

AbbVie40 participantsStarted Jul 2018

Los Angeles, California, United States • Tampa, Florida, United States • Chicago, Illinois, United States +19 more locations

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

UNITE Study: Understanding New Interventions With GBM ThErapy

Brain Cancer Trials in Other Cities

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Expanded Access Protocol Using 131I-MIBG

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Gliogene: Brain Tumor Linkage Study

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Other Conditions in Austin